Evidence map›Paper›PMID 29641549›Full record

ArticlePloS one2018

The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity.

Daniela Gentile, Matteo Fornai, Rocchina Colucci, Carolina Pellegrini, Erika Tirotta, Laura Benvenuti, Cristina Segnani, Chiara Ippolito, Emiliano Duranti, Agostino Virdis and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Role of apigenin in targeting metabolic syndrome: A systematic review.Iranian journal of basic medical sciences · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Heliyon · 2022
    Article
  14. Review
  15. Review
  16. Review
  17. Apigenin Modulates Dendritic Cell Activities and Curbs Inflammation Via RelB Inhibition in the Context of Neuroinflammatory Diseases.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Daniela GentileDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Matteo FornaiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.ORCID 0000-0002-0812-3959
Rocchina ColucciDepartment of Pharmaceutical and Pharmacological Science, University of Padova, Padova, Italy.
Carolina PellegriniDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Erika TirottaDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Laura BenvenutiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Cristina SegnaniDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Chiara IppolitoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Emiliano DurantiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Agostino VirdisDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sara CarpiDepartment of Pharmacy, University of Pisa, Pisa, Italy.
Paola NieriDepartment of Pharmacy, University of Pisa, Pisa, Italy.
Zoltán H NémethDepartment of Surgery, Morristown Medical Center, Morristown, New Jersey, United States of America.
Laura PistelliInterdepartmental Research Center "Nutraceuticals and Food for Health", University of Pisa, Pisa, Italy.
Nunzia BernardiniDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Corrado BlandizziDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Luca AntonioliDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
University of Pisa · ITMorristown Medical Center · USUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeApigenin can exert beneficial actions in the prevention of obesity. However, its putative action on obesity-associated bowel motor dysfunctions is unknown. This study examined the effects of apigenin on colonic inflammatory and motor abnormalities in a mouse model of diet-induced obesity. EXPERIMENTAL APPROACH: Male C57BL/6J mice were fed with standard diet (SD) or high-fat diet (HFD). SD or HFD mice were treated with apigenin (10 mg/Kg/day). After 8 weeks, body and epididymal fat weight, as well as cholesterol, triglycerides and glucose levels were evaluated. Malondialdehyde (MDA), IL-1β and IL-6 levels, and let-7f expression were also examined. Colonic infiltration by eosinophils, as well as substance P (SP) and inducible nitric oxide synthase (iNOS) expressions were evaluated. Motor responses elicited under blockade of NOS and tachykininergic contractions were recorded in vitro from colonic longitudinal muscle preparations. KEY

resultsWhen compared to SD mice, HFD animals displayed increased body weight, epididymal fat weight and metabolic indexes. HFD mice showed increments in colonic MDA, IL-1β and IL-6 levels, as well as a decrease in let-7f expression in both colonic and epididymal tissues. HFD mice displayed an increase in colonic eosinophil infiltration. Immunohistochemistry revealed an increase in SP and iNOS expression in myenteric ganglia of HFD mice. In preparations from HFD mice, electrically evoked contractions upon NOS blockade or mediated by tachykininergic stimulation were enhanced. In HFD mice, Apigenin counteracted the increase in body and epididymal fat weight, as well as the alterations of metabolic indexes. Apigenin reduced also MDA, IL-1β and IL-6 colonic levels as well as eosinophil infiltration, SP and iNOS expression, along with a normalization of electrically evoked tachykininergic and nitrergic contractions. In addition, apigenin normalized let-7f expression in epididymal fat tissues, but not in colonic specimens. CONCLUSIONS AND IMPLICATIONS: Apigenin prevents systemic metabolic alterations, counteracts enteric inflammation and normalizes colonic dysmotility associated with obesity.

Indexed as

Adipose TissueAnimalsApigeninBody WeightColonDiet, High-FatEosinophilsFlavonoidsGene Expression Regulation, EnzymologicInflammationInterleukin-1betaInterleukin-6MaleMalondialdehydeMiceMice, Inbred C57BLApigeninFlavonoidsInterleukin-1betaInterleukin-6MalondialdehydeMicroRNAsNitric Oxide Synthase Type IISubstance P

Identifiers

PMID29641549
PMCPMC5895026
OpenAlexW2797828151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.